Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Apr;2(2):70-75.
doi: 10.4021/wjon288w. Epub 2011 Apr 9.

Quality of Life in Patients Treated with Palliative Radiotherapy for Advanced Lung Cancer and Lung Metastases

Kaitlin Koo  1 , Liang Zeng  1 , Florencia Jon  1 , Emily Chen  1 , Kristopher Dennis  1 , Lori Holden  1 , Liying Zhang  1 , Amanda Caissie  1 , Janet Nguyen  1 , May Tsao  1 , Elizabeth Barnes  1 , Cyril Danjoux  1 , Arjun Sahgal  1 , Edward Chow  1
Affiliations

Quality of Life in Patients Treated with Palliative Radiotherapy for Advanced Lung Cancer and Lung Metastases

Kaitlin Koo et al. World J Oncol. 2011 Apr.

Abstract

Background: The purpose of this study was to investigate quality of life (QOL) in patients receiving palliative radiotherapy (RT) for advanced lung cancer/lung metastases using the EORTC QLQ-LC13 and the EORTC QLQ-C15-PAL questionnaires.

Methods: Patients who received palliative RT for lung metastases or advanced lung cancer between November 2007 and October 2010 completed the EORTC QLQ-LC13 and the QLQ-C15-PAL at baseline prior to RT, 1, 2, 4, 8 and 12 weeks post-treatment. The Wilcoxon Signed Rank test was used to compare QOL scores between baseline and each follow-up period.

Results: Thirty-one patients with advanced lung disease were included in this study; 61% of participants were male and 39% were female. The median age was 69 years (range 38 - 85), and median KPS and PPS scores at baseline were both 70 (range 30 - 90). All patients received radiotherapy to the lung. None of the QLQ-LC13 scores significantly improved or deteriorated at any follow-up. Of the QLQ-C15-PAL scales, fatigue, pain, insomnia and physical functioning significantly improved at their respective follow-ups.

Conclusions: This was the first study to use the EORTC QLQ-LC13 in conjunction with the EORTC QLQ-C15-PAL questionnaires. Future studies should continue to incorporate quality of life assessment tools specific to disease characteristics in advanced cancer patients.

Keywords: Advanced cancer; Lung; Metastases; QLQ-C15-PAL; QLQ-LC13; Quality of life; Radiotherapy.

PubMed Disclaimer

Conflict of interest statement

None

Figures

Figure 1
Figure 1
QLQ-C15-PAL scores with significant differences between follow-up and baseline.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Ozturk A, Sarihan S, Ercan I, Karadag M. Evaluating quality of life and pulmonary function of long-term survivors of non-small cell lung cancer treated with radical or postoperative radiotherapy. Am J Clin Oncol. 2009;32(1):65–72. doi: 10.1097/COC.0b013e31817e6ec2. - DOI - PubMed
    1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001;2(9):533–543. doi: 10.1016/S1470-2045(01)00486-7. - DOI - PubMed
    1. Muers MF, Round CE. Palliation of symptoms in non-small cell lung cancer: a study by the Yorkshire Regional Cancer Organisation Thoracic Group. Thorax. 1993;48(4):339–343. doi: 10.1136/thx.48.4.339. - DOI - PMC - PubMed
    1. Inoperable non-small-cell lung cancer (NSCLC): a Medical Research Council randomised trial of palliative radiotherapy with two fractions or ten fractions. Report to the Medical Research Council by its Lung Cancer Working Party. Br J Cancer. 1991;63(2):265–270. doi: 10.1038/bjc.1991.62. - DOI - PMC - PubMed
    1. A Medical Research Council (MRC) randomised trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small-cell lung cancer (NSCLC) and poor performance status. Medical Research Council Lung Cancer Working Party. Br J Cancer. 1992;65(6):934–941. doi: 10.1038/bjc.1992.196. - DOI - PMC - PubMed

LinkOut - more resources